#United States #Biopharmaceutical #Needham #oncology research #Perceptive Discovery

Perceptive Discovery Marks a New Era in Oncology Research

Perceptive Discovery, renowned for its role as a scientific partner to the global biopharmaceutical industry, has announced an impressive expansion of its in vitro laboratory capabilities at its facility located in Needham, Massachusetts. This pivotal move aims to bolster preclinical oncology research, thereby enhancing integrated workflows from early drug discovery to investigational new drug (IND)-enabling studies.

The expansion is substantial, featuring a five-fold increase in tissue culture space, which will enable a multitude of complex oncology workflows. Enhanced engineering controls and specialized laboratory environments have been introduced to optimize the research processes. Among the upgraded features are dedicated spaces for general tissue culture, as well as quarantine and clean-room divisions for the processing of pathogen-free cells, which are crucial for tumor inoculum preparation.

CEO Ben Murphy commented on the initiative, stating, “This expansion reflects our ongoing commitment to providing decision-ready data for oncology drug development, now at an industry-leading pace.” By scaling up both in vitro and ex vivo capabilities, Perceptive Discovery is equipping its partners with vital biological insights at earlier stages of drug development. This strategic enhancement is expected to conserve significant time and resources while guaranteeing higher chances of success in creating effective cancer therapies.

The newly augmented in vitro capabilities enable a wide array of critical assays vital for oncology and radiopharmaceutical development. These include radioligand binding studies, cellular phenotyping, mechanism-of-action analysis, and the development of biomarker-driven assays. This holistic approach ensures that Perceptive Discovery can cater effectively to its clients seeking innovative oncology solutions.

Moreover, by aligning these new capabilities with their established strengths in important areas such as in vivo imaging, radiochemistry, and dosimetry, Perceptive Discovery maintains a comprehensive approach to preclinical oncology research. This investment not only paves the way for enhanced biological insights but also supports informed, data-driven decisions for biopharma companies engaged in developing next-generation therapeutics, including radioligand therapies, biologics, and targeted oncology agents.

In conclusion, Perceptive Discovery's expansion represents a significant stride toward delivering advanced preclinical and translational solutions that bridge the gap between scientific innovation and clinical success. With a wealth of expertise in critical domains such as radiochemistry, oncology models, dosimetry, and assay development, the company stands poised to generate high-quality, decision-ready data for its biotech and pharmaceutical partners around the globe.

For more detailed insights into Perceptive Discovery’s offerings and capabilities, visit their official website.